China’s South–North Water Transfer Project (SNWTP) has the potential to transfer as much as 44.8 km³ year^-1 of water from the Yangtze River basin to the Yellow River basin. However, the SNWTP has not been assessed from a sustainability perspective. Thus, in this study we evaluated the SNWTP’s economic, social, and environmental impacts by reviewing the English literature published in journals that are part of the Web of Science database. We then synthesized this literature using a Triple Bottom Line framework of sustainability assessment. Our study has led to three main findings: (1) whether the SNWTP is economically beneficial depends largely on model assumptions, meaning that economic gains at the regional and national level are uncertain; (2) the SNWTP requires the resettlement of hundreds of thousands of people and challenges existing water management institutions, suggesting possible social concerns beyond the short term; and (3) evidently large environmental costs in water-providing areas and uncertain environmental benefits in water-receiving areas together point to an uncertain environmental future for the geographic regions involved. Thus, the overall sustainability of SNWTP is seriously questionable. Although much work has been done studying individual aspects of SNWTP’s sustainability, few studies have utilized the multi-scale, transdisciplinary approaches that such a project demands. To minimize environmental risks, ensure social equity, and sustain economic benefits, we suggest that the project be continuously monitored in all three dimensions, and that integrated sustainability assessments and policy improvements be carried out periodically.

Despite the fact that seizures are commonly associated with autism spectrum disorder (ASD), the effectiveness of treatments for seizures has not been well studied in individuals with ASD. This manuscript reviews both traditional and novel treatments for seizures associated with ASD. Studies were selected by systematically searching major electronic databases and by a panel of experts that treat ASD individuals. Only a few anti-epileptic drugs (AEDs) have undergone carefully controlled trials in ASD, but these trials examined outcomes other than seizures. Several lines of evidence point to valproate, lamotrigine, and levetiracetam as the most effective and tolerable AEDs for individuals with ASD. Limited evidence supports the use of traditional non-AED treatments, such as the ketogenic and modified Atkins diet, multiple subpial transections, immunomodulation, and neurofeedback treatments. Although specific treatments may be more appropriate for specific genetic and metabolic syndromes associated with ASD and seizures, there are few studies which have documented the effectiveness of treatments for seizures for specific syndromes. Limited evidence supports l-carnitine, multivitamins, and N-acetyl-l-cysteine in mitochondrial disease and dysfunction, folinic acid in cerebral folate abnormalities and early treatment with vigabatrin in tuberous sclerosis complex. Finally, there is limited evidence for a number of novel treatments, particularly magnesium with pyridoxine, omega-3 fatty acids, the gluten-free casein-free diet, and low-frequency repetitive transcranial magnetic simulation. Zinc and l-carnosine are potential novel treatments supported by basic research but not clinical studies. This review demonstrates the wide variety of treatments used to treat seizures in individuals with ASD as well as the striking lack of clinical trials performed to support the use of these treatments. Additional studies concerning these treatments for controlling seizures in individuals with ASD are warranted.

Five immunocompetent C57BL/6-cBrd/cBrd/Cr (albino C57BL/6) mice were injected with GL261-luc2 cells, a cell line sharing characteristics of human glioblastoma multiforme (GBM). The mice were imaged using magnetic resonance (MR) at five separate time points to characterize growth and development of the tumor. After 25 days, the final tumor volumes of the mice varied from 12 mm³ to 62 mm³, even though mice were inoculated from the same tumor cell line under carefully controlled conditions. We generated hypotheses to explore large variances in final tumor size and tested them with our simple reaction-diffusion model in both a 3-dimensional (3D) finite difference method and a 2-dimensional (2D) level set method. The parameters obtained from a best-fit procedure, designed to yield simulated tumors as close as possible to the observed ones, vary by an order of magnitude between the three mice analyzed in detail. These differences may reflect morphological and biological variability in tumor growth, as well as errors in the mathematical model, perhaps from an oversimplification of the tumor dynamics or nonidentifiability of parameters. Our results generate parameters that match other experimental in vitro and in vivo measurements. Additionally, we calculate wave speed, which matches with other rat and human measurements.